Our
News
Check back on a regualr basis
for futher updates.
VasoDynamics selects clinical trial sites across the UK and appoints Chief Investigator
VasoDynamics selects clinical trial sites across the UK and appoints Chief Investigator 30th June 2022 - VasoDynamics Ltd, the pharmaceutical company developing patient-friendly therapies for the prevention
VasoDynamics files global patent (PCT) for NG11-2 platform formulation and production
VasoDynamics files global patent (PCT) for NG11-2 platform formulation and production Platform Intellectual Property protection extended to 2042 5th March 2022 - VasoDynamics Ltd, the pharmaceutical
VasoDynamics strengthens Board and management team with key appointments
VasoDynamics strengthens Board and management team with key appointments Building a strong team of industry experts as clinical programmes progress • Paul Stainer, Director and Chief
VasoDynamics attracts £1.9m from new investors
VasoDynamics attracts £1.9m from new investors Additional funding to support the clinical development of NG11-2 30th November 2021 - VasoDynamics Ltd, the pharmaceutical company developing patient-friendly
VasoDynamics completes MHRA advisory meeting for NG11-2 clinical development
VasoDynamics completes MHRA advisory meeting for NG11-2 clinical development Phase Ib design and study objectives agreed 21st September 2021 - VasoDynamics Ltd, the pharmaceutical company developing
VasoDynamics appoints Gill Jennings & Every LLP of London.
VasoDynamics appoints Gill Jennings & Every LLP of London. By Gary Bower I 29th June 2021 Gill Jennings & Every (GJE) is a leading intellectual property
